Mary E. Gordinier
Expertise in
14
conditions

Dr. Mary E. Gordinier

Oncology
3991 Dutchmans Lane, Suite 405, 
Louisville, KY 
Accepting New Patients
35 Years of Experience
Expertise in
14
conditions
3991 Dutchmans Lane, Suite 405, 
Louisville, KY 

Overview

Mary Gordinier is an Oncologist practicing medicine in Louisville, Kentucky. She has been practicing medicine for over 35 years.

Dr. Gordinier is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Cervical Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Hernia Surgery.

Dr. Gordinier is board certified in American Board Of Obstetrics And Gynecology, Hospice And Palliative Medicine - 2010 , American Board Of Obstetrics And Gynecology, Gynecologic Oncology - 2003 , and American Board Of Obstetrics And Gynecology, Obstetrics And Gynecology - 2001. She is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 11 clinical trials. Dr. Gordinier is currently accepting new patients.

Graduate Institution

University Of Louisville School Of Medicine, Doctor Of Medicine, 1991

Residency

Women & Infants Hospital of Rhode Island GME, Obstetrics & Gynecology, 1995

Specialties

Oncology

Licenses

Obstetrics & Gynecology in KY

Board Certifications

American Board Of Obstetrics And Gynecology, Hospice And Palliative Medicine - 2010
American Board Of Obstetrics And Gynecology, Gynecologic Oncology - 2003
American Board Of Obstetrics And Gynecology, Obstetrics And Gynecology - 2001

Fellowships

University of Texas M.D. Anderson Cancer Center, 2000
Women & Infants Hospital RI, 1997

Hospital Affiliations

Norton Hospitals, Inc

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
MHS
  • EPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Norton Cancer Institute - St. Matthews
3991 Dutchmans Lane, Suite 405, Louisville, KY 40207

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: February 24, 2026
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed
Study Phase: Phase 3
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Paclitaxel, Ruxolitinib phosphate
Study Phase: Phase 1/Phase 2
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 3
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Device, Drug
Study Drug: Paclitaxel
Study Phase: Phase 3
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: July 25, 2023
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

7 Total Publications

Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer.
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer.
Journal: Journal of gynecologic oncology
Published: May 28, 2024
Similar Doctors
Expertise in
15
conditions
Dr. Jason Chesney
Oncology
Expertise in
15
conditions
Dr. Jason Chesney
Oncology
Referral may be required

Uofl Health-Brown Cancer Center

529 S Jackson St, 
Louisville, KY 
 (0.4 miles away)
502-562-4673
Languages Spoken:
English
See accepted insurances

Jason Chesney is an Oncologist practicing medicine in Louisville, Kentucky. Dr. Chesney is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Melanoma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Pleuropulmonary Blastoma.

Expertise in
15
conditions
Dr. Arash Kalebasty
Oncology
Expertise in
15
conditions
Dr. Arash Kalebasty
Oncology
Referral may be required

Norton Cancer Institute-Clark

301 Gordon Gutmann Blvd Ste 301, 
Jeffersonville, IN 
 (6.7 miles away)
502-629-2500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arash Kalebasty is an Oncologist practicing medicine in Jeffersonville, Indiana. Dr. Kalebasty is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Familial Prostate Cancer, Urothelial Cancer, Renal Cell Carcinoma (RCC), Orchiectomy, and Nephrectomy.

Expertise in
21
conditions
Dr. Daniel S. Metzinger
Oncology
Expertise in
21
conditions
Dr. Daniel S. Metzinger
Oncology
Referral may be required

University Of Louisville Physicians - Obstetrics And Gynecology - Women's Health

6420 Dutchmans Parkway, Suite 190, 
Louisville, KY 
 (6.0 miles away)
502-561-7220
Experience:
32+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Metzinger is an Oncologist practicing medicine in Louisville, Kentucky. He has been practicing medicine for over 32 years. Dr. Metzinger is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Malignant Mixed Mullerian Tumor, Vulvar Cancer, Hysterectomy, and Oophorectomy. Dr. Metzinger is board certified in American Board Of Obstetrics And Gynecology, Gynecologic Oncology - 2007 and American Board Of Obstetrics And Gynecology, Obstetrics And Gynecology - 2003. Dr. Metzinger is currently accepting new patients.

Frequently Asked Questions about Dr. Mary E. Gordinier

How do I make an appointment with Dr. Mary E. Gordinier?

You can book an appointment with Dr. Mary E. Gordinier by calling their office at 502-899-3366. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mary E. Gordinier a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mary E. Gordinier is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mary E. Gordinier specialize in?

While Dr. Mary E. Gordinier is a Oncology, they have specific expertise in Ovarian Cancer, Cervical Cancer, and Ovarian Carcinosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Mary E. Gordinier participate in research or clinical trials?

Yes. Dr. Mary E. Gordinier has published 7 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Mary E. Gordinier's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mary E. Gordinier accept my insurance?

Dr. Mary E. Gordinier accepts most major insurance plans, including Aetna and Ambetter. We recommend calling the office directly at 502-899-3366 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gordinier's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 26 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile